Navigation Links
Genzyme Launches Cholestagel(R) in Europe
Date:10/23/2007

rolemia (FH) -- an inherited disorder that causes exceptionally high levels of LDL-cholesterol -- who cannot reach their target LDL- cholesterol levels with a maximum regimen of statins and ezetimibe alone.

This double-blind, randomized "TRIPLE" study will involve 80 patients with FH enrolled in six European centers (including in the UK, Netherlands, Sweden and France) and preliminary results are expected in Q3 2008.

"Patients with genetic conditions like familial hypercholesterolemia are at particularly high risk of early coronary heart disease," said Dr. Anthony Wierzbicki, from London's St. Thomas' Hospital and a board member and chairman of the Medical Scientific and Research Committee of FH patient association 'Heart UK'. "Patients have to take multiple cholesterol-lowering therapies and yet still often require further cholesterol reduction to reach target lipid levels recommended for patients at risk of cardiovascular events. New non-systemic agents are a welcome addition for these patients to help them achieve these targets."

Unlike most other cholesterol-lowering treatments, Cholestagel is non- systemic, and therefore is not absorbed into the bloodstream. Cholestagel binds bile acids in the intestine, impeding their reabsorption. This process -- called bile acid sequestration -- results in an increased clearance of LDL cholesterol from the blood. Cholestagel is also well tolerated, with minimal gastrointestinal side effects similar to those seen in placebo, and has limited drug-interaction.

Colesevelam has been approved for use in the United States since 2000, where it is marketed by Daiichi Sankyo Inc. under the trade name WelChol(R). Genzyme plans to launch Cholestagel in the United Kingdom, the Netherlands and the Scandinavian region this quarter, and in additional European countries next year. Genzyme also intends to pursue regulatory approvals for Cholestagel in Latin America, Canada, and the Asia Pacific region.

Genzyme ha
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cytochroma settles lawsuit with Genzyme
2. Genzyme sues former Bone Care employees
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. Merge launches diagnostic mammography workstation in Europe
5. Einstein Wireless launches cellular alert system
6. Logistics Health launches compliance management tool
7. UW-Madison launches new high-speed research network
8. UWM launches research foundation
9. TeraMedica launches information manager
10. GE Healthcare launches hybrid electronic record
11. Cedara launches new version of DICOM toolkit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2014)... , July 17, 2014  Vanda Pharmaceuticals Inc. ... focused on the development and commercialization of products for ... it will release results for the second quarter of ... opens. The Company will host a ... 7, 2014, during which Vanda management will discuss the ...
(Date:7/17/2014)...  Prana Biotechnology (NASDAQ: PRAN ; ASX: ... development program for Alzheimer,s disease. Professor ... Mental Health, The University of Melbourne, will today include ... in his presentation at the Alzheimer,s Association International Conference ... The presentation is entitled: "How to change and ...
(Date:7/17/2014)... all know, some optical devices can only work with ... polarizer is necessary to shift the polarization direction of ... half-wave plate, which constructed out of a birefringent material ... half-wave plate depends on the thickness of the crystal, ... a half-wave plate is difficulty to integrate on circuits. ...
(Date:7/17/2014)... , July 17, 2014  Exelixis, Inc. (Nasdaq: ... company. EXEL developed two cancer treatments cabozantinib (Cabo, Cometriq) ... active component. The company has a partnership with Roche ... to earn approval in the treatment of melanoma by ... week. Cabo is marketed and distributed in the U.S. ...
Breaking Biology Technology:Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014 2Prana Alzheimer's disease Development Program update 2Prana Alzheimer's disease Development Program update 3Prana Alzheimer's disease Development Program update 4Prana Alzheimer's disease Development Program update 5Exelixis, Inc., Analyst Report; The Upside Potential is Worth the Risk by BrokerBank Securities, Inc. 2
... Inc. (TSX:SDI), a company developing products for the ... International Symposium on Intensive Care and Emergency Medicine ... feature a key scientific symposium entitled, "The Role ... thought leaders in the field of sepsis. Presentations ...
... - Up to $50 Million Potential Milestones plus Double ... Host Conference Call at 11:00 a.m. ET Today - ... Amex: NBY ), a mid-stage biopharmaceutical company ... of a wide range of infections without causing resistance, ...
... 23, 2009 Reston, Va. The American Institute ... for Composites (ASC) congratulate the winners of the inaugural ... Distinguished Professor of Mechanical and Aerospace Engineering at the ... A. Armstrong Distinguished Professor of Aeronautical and Astronautical Engineering ...
Cached Biology Technology:Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin 2NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions 2NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions 3NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions 4NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions 5NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions 6Professors Raphael Haftka and C. T. Sun to receive AIAA-ASC James H. Starnes Jr. Award 2
(Date:7/21/2014)... and think, "Of course! Why didn,t I think of ... own invention, sparking ideas and building possibilities. This type ... Station Program Science Office,s new 15-book Researcher,s Guide Series. ... in orbit, their mental wheels may begin to speed ... propose new research and potentially make discoveries that they ...
(Date:7/21/2014)... Lgar,s team at the INRS nergie Matriaux Tlcommunications ... a spatial and temporal resolution greatly exceeding that ... a femtosecond laser source to shoot a molecular ... vinylidene. An article presenting the advancement was recently ... . , "The approach we developed combines ...
(Date:7/21/2014)... -- Why does the word "dog" have meaning? If ... friend understand you? , Kansas State University philosopher Elliott ... his latest research, which focuses on long-standing philosophical questions ... two other philosophers and a mathematician are collaborating to ... acquires meaning. , "If I order a cappuccino at ...
Breaking Biology News(10 mins):International Space Station researcher guides aim to maximize science 2International Space Station researcher guides aim to maximize science 3International Space Station researcher guides aim to maximize science 4Philosopher uses game theory to understand how words, actions acquire meaning 2
... [Brown University] A computerized epidemiological model of the spread ... California in 2005 successfully predicted where 81.6 percent of human ... where the risk of infection turned out to be 39 ... research. The DYCAST software used in those predictions is now ...
... cells is a well-oiled machine with tiny protein motors hauling ... molecular motors are responsible for a variety of critical transport ... can put themselves into "energy save mode" to conserve cellular ... the cell, and when. A new study ...
... may not sound very glamorous, a new method of ... news for both confined animal operations and environmental groups, ... The method uses gas-permeable membrane technology that tests have ... in liquid manure in 20 days. The removed ammonium ...
Cached Biology News:Software predicted risk in California West Nile virus epidemic 2Carnegie Mellon scientists discover how molecular motors go into 'energy save mode' 2Carnegie Mellon scientists discover how molecular motors go into 'energy save mode' 3New technology could capture ammonia from liquid manure 2New technology could capture ammonia from liquid manure 3
GOAT ANTI FRK...
... Spots and complementary RNA Spikes for the ... for glass array printing and for protocol ... cDNA labeling, hybridization stringency and background. Normalize ... Spots and Oligo Spots, and complementary RNA ...
MOUSE ANTI S. MUTANS PEPTIDOGLYCAN...
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
Biology Products: